OCREVUS's safety and efficacy for PPMS were studied in over 700 patients.

The ORATORIO trial for PPMS 3,18

The efficacy and safety of OCREVUS (ocrelizumab) for PPMS were studied in over 700 patients in a placebo-controlled trial.

OCREVUS® (ocrelizumab) has demonstrated effectiveness in PPMS

Demonstrated effectiveness in PPMS 3,18

OCREVUS was proven in PPMS across key clinical and MRI measures of efficacy and safety.

For more than five years the safety of OCREVUS® (ocrelizumab) was studied and demonstrated in ORATORIO.

OCREVUS safety profile for PPMS 2,3,15

The safety of OCREVUS for PPMS was studied in the >2-year ORATORIO clinical trial and in over 3 years of open-label extension study with no change to the risk-benefit profile since launch.

PPMS=primary progressive multiple sclerosis.